Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Bull NYU Hosp Jt Dis. 2007;65(3):215-21.

Hyperuricemia and gout: new insights into pathogenesis and treatment.

Author information

  • 1New York University School of Medicine and Division of Rheumatology, NYU Hospital for Joint Diseases, New York, NY 10003, USA. michael.pillinger@med.nyu.edu

Abstract

Over the past decade, significant advances have been made regarding the pathogenesis, clinical implications, and treatment of hyperuricemia. While physicians have understood for at least a century that uric acid causes gout, we are now beginning to address the question of why hyperuricemia exists and the mechanisms by which uric acid acts to stimulate inflammation. This review focuses on (1) previously unknown biological roles of uric acid; (2) why the loss of the uricase gene and resultant hyperuricemia may have provided an evolutionary advantage to primates and, in particular, to humans; (3) the molecular effects of uric acid on inflammatory cells; and (4) novel antihyperuricemic agents currently under study.

PMID:
17922673
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Bulletin of the NYU Hospital for Joint Diseases
    Loading ...
    Write to the Help Desk